entertainment -WSS

entertainment

author：focus 2025-09-28 01:39:58 - browse：4

The bacterium A. baylyi was engineered to detect a common cancer mutation. Courtesy of Josephine Wright

Dan Worthley, a gastroenterologist and cancer scientist at Colonoscopy Clinic in Brisbane, Australia, does thousands of colonoscopies a year, seeking and destroying precancerous polyps. It’s a practically surefire way to prevent colorectal cancer, but an unpleasant experience for patients. The future, Worthley hopes, will be much less onerous — and he’s developing a technology that, if it works one day, might make the experience more of a piece of cake.

Or, rather, a cup of yogurt — containing engineered bacteria that can detect and deliver a treatment for colorectal polyps or cancer. Worthley and colleagues at the University of California, San Diego, and the University of Adelaide published results in Science on Thursday that show they are one step closer to that far-off dream. In their paper, the researchers show a proof-of-concept engineered bacterium that can detect cancer DNA in the guts of mice and react to it by turning on certain cellular circuitry.

“I think it’s really cool. It introduces a new concept for how you can use cells as a sensor for something happening inside other cells,” said Mikhail Shapiro, a chemical and medical engineer at the California Institute of Technology who did not work on the study. “That can flip a switch inside those cells. In this case, it’s used for diagnostic output, but in principle it could be used for other things.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： eGenesis tests gene

WSS

Fertility clinic egg and embryo storage is a disaster

EU regulator recommends expanding Mounjaro approval to obesity

Test for long Covid? Researchers find new clue in blood samples

Dewpoint Therapeutics lays off staff after losing partnerships

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Dewpoint Therapeutics lays off staff after losing partnerships

hotspot

entertainment

hotspot

What does generative AI mean for health care? We asked experts

WuXi Biologics beefs up its lobbying operation

In Memoriam: Notable people who died in 2023

What a koala virus tells us about the human genome

The high cost of giving birth even with insurance

Novo Nordisk testing Wegovy against alcohol

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Biotech venture capitalists face new demands from investors

United colonoscopy coverage change 'may cost lives,' doctors say

STAT series 'Denied by AI' wins major journalism prizes

explore

CVS is willing to dump 10% of its Medicare Advantage members

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

CVS is willing to dump 10% of its Medicare Advantage members

STAT reporters are Pulitzer Prize finalists for investigative reporting

The surgeon had a dilemma only a Nazi medical text could resolve

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

hotspot

explore

leisure time

leisure time